Meeting Presentations | Drugs
CDER professionals participate in several meetings, conferences and workshops throughout the year. Appealing primarily to the pharmaceutical industry and health care professionals, topics can range from users fees, to drug advertising and marketing, to genomics, to over-the-counter products. Materials and overviews from some of those meetings are listed in the presentations library.
2021 Presentations
Title | Presenter(s) | Date |
---|---|---|
FDA Role in Regulation of Cannabis Products (PDF - 1.67 MB) | Douglas C. Throckmorton, MD | 9/16/2021 |
2019 Presentations
Title | Presenter(s) | Date |
---|---|---|
CDER New Drugs Program: 2019 Update (PDF - 1.32MB) | Khushboo Sharma, MBA, RAC | 12/3/2019 |
Generic Drug Program Update (PDF - 135 KB) | Sally Choe, PhD | 4/2019 |
New Drugs Regulatory Program Modernization (PDF - 167 KB) | Janet Woodcock, MD | 4/2019 |
Search for Balance: FDA’s Approach to the Opioids Crisis (PDF - 2 MB) | Douglas C. Throckmorton, MD | 3/9/2019 |
FDA Role in Regulation of Cannabis Products (PDF - 88 KB) | Sharon Lindan Mayl, J.D. | 2/2019 |
Ongoing FDA Work Related to Opioid Overdose Prevention (PDF - 1.5 MB) | Douglas C. Throckmorton, MD | 1/2019 |
2018 Presentations
Title | Presenter(s) | Date |
---|---|---|
Search for Balance: FDA’s Approach to the Opioids Crisis (PDF - 2 MB) | Douglas C. Throckmorton, MD | 3/9/2019 |
Federal Efforts to Prevent Drug Shortages An FDA Perspective (PDF - 66 KB) | Douglas C. Throckmorton, MD | 12/27/2018 |
Charge to the Committee (PDF - 1MB) | Douglas C. Throckmorton, MD | 12/13/2018 |
Addressing Opioids: The FDA Response to Challenges in Public Health (PDF - 1 MB) | Douglas C. Throckmorton, MD | 12/12/2018 |
CDER New Drugs Program: 2018 Update (PDF - 977 KB) | Khushboo Sharma, MBA, RAC | 12/11/2018 |
CDER Office of Surveillance and Epidemiology: 2018 Update (PDF - 2 MB) | Gerald J. Dal Pan, MD, MHS | 12/11/2018 |
FDA Update on Drug Compounding (PDF - 1 MB) | Julie Dohm, J.D., Ph.D. | 10/04/2018 |
FDA Center Updates: CDER (PDF - 409 KB) | Douglas C. Throckmorton, M.D. | 9/26/2018 |
OGD Update: Welcome to much more than GDUFA II (PDF - 847 KB) | Kathleen Uhl, M.D. | 9/7/2018 |
FDA Update: 2018 (PDF - 975 KB) | Douglas C. Throckmorton, M.D. | 5/21/2018 |
FDA Update: 2018 (PDF - 1 MB) | Douglas C. Throckmorton, M.D. | 5/17/2018 |
Update: Biosimilar Program in the U.S. (PDF - 236 KB) | Leah Christl, Ph.D. | 4/27/2018 |
Biosimilar Regulatory Policy: Understanding the Landscape and Relevance to Medical Practice (PDF - 584 KB) | Sue Lim, M.D. | 4/14/2018 |
Biosimilar and Interchangeable Products: The U.S. FDA Perspective (PDF - 313 KB) | Joe Franklin, J.D., Ph.D. | 4/14/2018 |
FDA's Actions to Address the Opioid Epidemic (PDF - 1MB) | Douglas C. Throckmorton, M.D. | 3/14/2018 |
The Role of Social Science in Prescription Drug Promotion at FDA and Preview of Upcoming Studies (PDF - 282 KB) | Kathryn J. Aikin, Ph.D. | 3/9/2018 |
2017 Presentations
2016 Presentations have been archived. To view them, please see the FDA Archive
2012-2015 Presentations have been archived. To view them, please see the FDA Archive.
2012-2015 Presentations have been archived. To view them, please see the FDA Archive.